1. Home
  2. MXCT vs NNNN Comparison

MXCT vs NNNN Comparison

Compare MXCT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

SELL

Current Price

$3.43

Market Cap

154.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MXCT
NNNN
Founded
1999
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
154.1M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
MXCT
NNNN
Price
$1.38
$3.43
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $4.11
N/A
AVG Volume (30 Days)
★ 1.4M
31.3K
Earning Date
11-10-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $33,026,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$10.06
N/A
P/E Ratio
★ N/A
$446.57
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$3.09
52 Week High
$1.80
$44.73

Technical Indicators

Market Signals
Indicator
MXCT
NNNN
Relative Strength Index (RSI) 55.07 38.09
Support Level $1.02 $3.21
Resistance Level $1.54 $4.43
Average True Range (ATR) 0.14 0.37
MACD -0.01 0.05
Stochastic Oscillator 70.41 5.86

Price Performance

Historical Comparison
MXCT
NNNN

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: